Week in Review Fosun in $2 Billion Bidding War for US Rights to Novartis’ Generic Drugs

Deals and Financings Fosun Pharma is one of the finalists in a $2 billion bidding war for part of Novartis' US portfolio of generic drugs;China Resources Pharma is in talks to pay $613 million for a c…
Read the full story: Bioportfolio Latest News